Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis

Cancer

Volumn 109, Issue 4, 2007, Pages 751-760

  Fortin, David ^a   Gendron, Cathy ^a   Boudrias, Marie ^a   Garant, Marie Pierre ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Blood brain barrier disruption; Brain metastasis; Chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; OVARY CARCINOMA; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LUNG NEOPLASMS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; OSMOSIS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33846917730     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22450     Document Type: Article

References (36)

1. Patchell RA. The management of brain metastasis. Cancer Treat Rev. 2003;29:533-540.
2. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249:1357-1369.
3. Tsao MN, Sultamen K, Chiu D, et al. Supportive care management of brain metastases: what is known and what we need to know (NCIC). Clin Oncol. 2003;15:429-434.
4. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Oncol Biol Phys. 1997;37:745-751.
5. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol. 2004;52:199-215.
6. Metha MP, Khuntia D, Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery. 2005;57:s4-33-44.
7. Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002;38:487-496.
8. Andrews DW, Scott CB, Sperduto PW. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-1672.
9. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-796.
10. Fortin D. La barriere hemato-encephalique: un facteur cle en neuro-oncologie. Rev Neurol. 2004;160:523-532.
11. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3-14.
12. Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol. 2002;59:35-40.
13. Newton HB, Slivka MA, Volpi C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol. 2003;61:35-44.
14. Newton HB, Figg GM, Slone HW, Bourekas E. Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. J Neurooncol. 2006;78:157-160.
15. Kraemer D, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Curr Neurol Neurosci Rep. 2002;2:216-224.
16. Fortin D, Desjardins A, Benko A, Boudrias M. Blood-brain barrier disruption enhanced chemotherapy in the treatment of malignant brain tumors: the Sherbrooke experience. Cancer. 2005;103:2606-2615.
17. Fortin D, Salame J, Desjardins A, Benko A. Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. Am J Neuroradiol. 2004;25:830-834.
18. Duffey P, Chari G, Cartlidge NE, Shaw PJ. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation: a new facet in the clinical spectrum of radiation encephalopathy. Arch Neurol. 1996;53:814-818.
19. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083-1100.
20. Sato S, Kawase T, Harada S, Takayama H, Suga S. Effect of hypersomotic solutions on human brain tumour vasculature. Acta Neurochir. 1998;140:1135-1142.
21. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
22. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by TNF-alpha and LPS. Mol Pharmacol. 2006;69:462-470.
23. Kraemer D, McAllister L, Fortin D, Doolittle N, Neuwelt EA. Association of drug delivery and clinical outcomes in human non-AIDS primary CNS lymphoma as a model to assess the impact of total dose intensity delivered to the CNS. Neurosurgery. 2001;48:1033-1041.
24. Ebert BL, Niemierko E, Shaffer K, Salqia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003;8:69-75.
25. Postmus PE, Haaxma-Reiche H, Gregor A, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol. 1998;46:251-260.
26. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10:753-759.
27. Anupol N, Ghamande S, Odunsi K, Driscoll D, Lele S. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastasis. Gynecol Oncol. 2002;85:487-492.
28. Melichar B, Urminske H, Kohlova T, Nova M, Cesak T. Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of literature. Gynecol Oncol. 2004;94:267-276.
29. Micha JP, Goldstein BH, Hunter JV et al. Long-term survival in an ovarian cancer patient with brain metastases. Gynecol Oncol. 2004;92:978-980.
30. McMeekin SD, Kamelle SA, Vasilev SA, et al. Ovarian cancer metastatic to the brain: what is the optimal management? J Surg Oncol. 2001;78:194-201.
31. Boogerd G, Cuzzoni Q, Strada MR, et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69:972-980.
32. Subramanian A, Harris A, Piggot K, et al. Metastasis to and from the central nervous system - the relatively protected site. Lancet Oncol. 2002;3:498-507.
33. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie. 2002;25:474-479.
34. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001;12:249-254.
35. Hoerni-Simon G, Suchaud JR Eghbali H, et al. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. Oncology. 1987;44:98-101.
36. MacDonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.